Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.57 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.47 |
| ▸ | TK1 | P04183 | 1/20 | 0.44 |
| ▸ | TK2 | O00142 | 11/20 | 0.43 |
| ▸ | DUT | P33316 | 1/20 | 0.39 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | SLC6A1 | P30531 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17377651 | 0.98 | KIF11 (0.55) | KIF11HRH4TK1TK2DUT | |
| SCHEMBL913220 | 0.98 | KIF11 (0.55) | KIF11HRH4TK1TK2DUT | |
| SCHEMBL20032419 | 0.98 | KIF11 (0.55) | KIF11HRH4TK1TK2DUT | |
| SCHEMBL913478 | 0.94 | KIF11 (0.59) | KIF11HRH4TK1TK2DUT | |
| SCHEMBL4012213 | 0.85 | KIF11 (0.63) | KIF11HRH4TK1TK2DUT | |
| SCHEMBL6891571 | 0.81 | KIF11 (0.48) | KIF11HRH4TK2SLC6A1 | |
| SCHEMBL11275984 | 0.80 | KIF11 (0.74) | KIF11HRH4TK1TK2DUT | |
| SCHEMBL5280961 | 0.80 | KIF11 (0.57) | KIF11HRH4TK1TK2DUT | |
| SCHEMBL17243243 | 0.80 | KIF11 (0.57) | KIF11HRH4TK1TK2TSHR | |
| SCHEMBL8868959 | 0.80 | KIF11 (0.57) | KIF11HRH4TK1TK2DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357134-A1 | AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS | UCL BUSINESS LTD (GB) | 2023-11-09 | — | — | US | disclosed |
| US-20230357134-A1 | AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS | UCL BUSINESS LTD (GB) | 2023-11-09 | — | — | US | disclosed |
| EP-4214189-A1 | AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS | UCL Business Ltd (GB) | 2023-07-26 | — | — | EP | disclosed |
| WO-2022058733-A1 | AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS | UCL BUSINESS PLC (GB) | 2022-03-24 | — | — | WO | disclosed |
| EP-2074126-A2 | SULFAMOYL-CONTAINING DERIVATIVES AND USES THEREOF | Wyeth a Corporation of the State of Delaware (US) | 2009-07-01 | — | — | EP | disclosed |
| US-20080096903-A1 | SULFAMOYL-CONTAINING DERIVATIVES AND USES THEREOF | WYETH (US) | 2008-04-24 | — | — | US | disclosed |
| WO-2008049105-A2 | SULFAMOYL-CONTAINING DERIVATIVES AND USES THEREOF | WYETH (US) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096903-A1 | SULFAMOYL-CONTAINING DERIVATIVES AND USES THEREOF | HSP90AB2P, HSP90AB1, HSP90AA1 | KIF11 3711/4885HRH4 3079/4885TK1 551/4885 |
| US-20230357134-A1 | AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS | TTR, C1R, APOB | KIF11 4366/4885HRH4 928/4885TK1 3003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.